Press Releases
January 23, 2024 - FUJIFILM Cellular Dynamics and Opsis Therapeutics Announce License with BlueRock Therapeutics for iPSC-derived Cell Therapy Candidate
August 31, 2022 - First U.S. patient receives autologous stem cell therapy to treat dry AMD
About Opsis
Retinal degenerative diseases cause irreversible vision loss in tens of millions of patients worldwide.
Our mission at Opsis Therapeutics is to advance a pipeline of first-in-class cell replacement therapies targeting Age-Related Macular Degeneration (AMD) and a broad range of inherited retinal disorders including Retinitis Pigmentosa.
Opsis’ technology platform builds upon recent advances that enable scalable manufacture of authentic human retinal cells from induced-pluripotent stem cells.